// App-Quantinova.ai

: EXTH-46. ALISERTIB POTENTIATES THE EFFECT OF CABOZANTINIB AND VANDETANIB AGAINST GLIOBLASTOMA CELLS

Researchers

Presenter

  • Brian Williams

Principal Investigators

  • Cory Zumbar

  • Caroline Mifsud

  • Kendall Smith

  • Muge Sak

  • Norman Lehman

Medical Centers

  • N/A

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

  • Brain cancer

Biomarkers

  • Annexin V

  • Aurora kinase A

  • Kinase Insert Domain Receptor

  • Vascular endothelial growth factor A

Drug/Treatment

  • Cabozantinib

  • Vandetanib

  • Alisertib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved